Page 582 - Williams Hematology ( PDFDrive )

556 Part VI: The Erythrocyte Chapter 37: Anemia of Chronic Disease 557

103. Susantitaphong P, Alqahtani F, Jaber BL: Efficacy and safety of intravenous iron therapy 106. Radtke HW, Claussner A, Erbes PM, et al: Serum erythropoietin concentration in
for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am J chronic renal failure: Relationship to degree of anemia and excretory renal function.
Nephrol 39:130, 2014. Blood 54:877, 1979.
104. Litton E, Xiao J, Ho KM: Safety and efficacy of intravenous iron therapy in reducing 107. Rossert J, Casadevall N, Eckardt KU: Anti-erythropoietin antibodies and pure red cell
requirement for allogeneic blood transfusion: Systematic review and meta-analysis of aplasia. J Am Soc Nephrol 15:398, 2004.
randomised clinical trials. BMJ 347:f4822, 2013. 108. Epoetin: For better or for worse? Lancet Oncol 5:1, 2004.
105. Brookhart MA, Freburger JK, Ellis AR, et al: Infection risk with bolus versus mainte- 109. Bohlius J, Weingart O, Trelle S, et al: Cancer-related anemia and recombinant human
nance iron supplementation in hemodialysis patients. J Am Soc Nephrol 24:1151, 2013. erythropoietin—an updated overview. Nat Clin Pract Oncol 3:152, 2006.

Kaushansky_chapter 37_p0549-0558.indd 557 9/17/15 6:17 PM